While clinical studies indicate that IDO1 inhibitors alone have limited anti-tumor effects, their combination with other immunotherapies, such as checkpoint inhibitors, demonstrates synergistic potential to improve survival rates [47]. Here, IDO1 is linked to neoplasm.